The reflux disease questionnaire: A measure for assessment of treatment response in clinical trials

Michael Shaw, John Dent, Timothy Beebe, Ola Junghard, Ingela Wiklund, Tore Lind, Folke Johnsson

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Background: Critical needs for treatment trials in gastroesophageal reflux disease (GERD) include assessing response to treatment, evaluating symptom severity, and translation of symptom questionnaires into multiple languages. We evaluated the previously validated Reflux Disease Questionnaire (RDQ) for internal consistency, reliability, responsiveness to change during treatment and the concordance between RDQ and specialty physician assessment of symptom severity, after translation into Swedish and Norwegian. Methods: Performance of the RDQ after translation into Swedish and Norwegian was evaluated in 439 patients with presumed GERD in a randomized, double-blind trial of active treatment with a proton pump inhibitor. Results: The responsiveness was excellent across three RDQ indicators. Mean change scores in patients on active treatment were large, also reflected in effect sizes that ranged from a low of 1.05 (dyspepsia) to a high of 2.05 (heartburn) and standardized response means 0.99 (dyspepsia) and 1.52 (heartburn). A good positive correlation between physician severity ratings and RDQ scale scores was seen. The internal consistency reliability using alpha coefficients of the scales, regardless of language, ranged from 0.67 to 0.89. Conclusion: The results provide strong evidence that the RDQ is amenable to translation and represents a viable instrument for assessing response to treatment, and symptom severity.

Original languageEnglish (US)
Article number31
JournalHealth and Quality of Life Outcomes
Volume6
DOIs
StatePublished - Apr 30 2008

Fingerprint

Clinical Trials
Heartburn
Dyspepsia
Gastroesophageal Reflux
Therapeutics
Language
Physicians
Symptom Assessment
Proton Pump Inhibitors
Surveys and Questionnaires

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

The reflux disease questionnaire : A measure for assessment of treatment response in clinical trials. / Shaw, Michael; Dent, John; Beebe, Timothy; Junghard, Ola; Wiklund, Ingela; Lind, Tore; Johnsson, Folke.

In: Health and Quality of Life Outcomes, Vol. 6, 31, 30.04.2008.

Research output: Contribution to journalArticle

Shaw, Michael ; Dent, John ; Beebe, Timothy ; Junghard, Ola ; Wiklund, Ingela ; Lind, Tore ; Johnsson, Folke. / The reflux disease questionnaire : A measure for assessment of treatment response in clinical trials. In: Health and Quality of Life Outcomes. 2008 ; Vol. 6.
@article{ba0c0b94a7234579bba54f47a68b364b,
title = "The reflux disease questionnaire: A measure for assessment of treatment response in clinical trials",
abstract = "Background: Critical needs for treatment trials in gastroesophageal reflux disease (GERD) include assessing response to treatment, evaluating symptom severity, and translation of symptom questionnaires into multiple languages. We evaluated the previously validated Reflux Disease Questionnaire (RDQ) for internal consistency, reliability, responsiveness to change during treatment and the concordance between RDQ and specialty physician assessment of symptom severity, after translation into Swedish and Norwegian. Methods: Performance of the RDQ after translation into Swedish and Norwegian was evaluated in 439 patients with presumed GERD in a randomized, double-blind trial of active treatment with a proton pump inhibitor. Results: The responsiveness was excellent across three RDQ indicators. Mean change scores in patients on active treatment were large, also reflected in effect sizes that ranged from a low of 1.05 (dyspepsia) to a high of 2.05 (heartburn) and standardized response means 0.99 (dyspepsia) and 1.52 (heartburn). A good positive correlation between physician severity ratings and RDQ scale scores was seen. The internal consistency reliability using alpha coefficients of the scales, regardless of language, ranged from 0.67 to 0.89. Conclusion: The results provide strong evidence that the RDQ is amenable to translation and represents a viable instrument for assessing response to treatment, and symptom severity.",
author = "Michael Shaw and John Dent and Timothy Beebe and Ola Junghard and Ingela Wiklund and Tore Lind and Folke Johnsson",
year = "2008",
month = "4",
day = "30",
doi = "10.1186/1477-7525-6-31",
language = "English (US)",
volume = "6",
journal = "Health and Quality of Life Outcomes",
issn = "1477-7525",
publisher = "BioMed Central",

}

TY - JOUR

T1 - The reflux disease questionnaire

T2 - A measure for assessment of treatment response in clinical trials

AU - Shaw, Michael

AU - Dent, John

AU - Beebe, Timothy

AU - Junghard, Ola

AU - Wiklund, Ingela

AU - Lind, Tore

AU - Johnsson, Folke

PY - 2008/4/30

Y1 - 2008/4/30

N2 - Background: Critical needs for treatment trials in gastroesophageal reflux disease (GERD) include assessing response to treatment, evaluating symptom severity, and translation of symptom questionnaires into multiple languages. We evaluated the previously validated Reflux Disease Questionnaire (RDQ) for internal consistency, reliability, responsiveness to change during treatment and the concordance between RDQ and specialty physician assessment of symptom severity, after translation into Swedish and Norwegian. Methods: Performance of the RDQ after translation into Swedish and Norwegian was evaluated in 439 patients with presumed GERD in a randomized, double-blind trial of active treatment with a proton pump inhibitor. Results: The responsiveness was excellent across three RDQ indicators. Mean change scores in patients on active treatment were large, also reflected in effect sizes that ranged from a low of 1.05 (dyspepsia) to a high of 2.05 (heartburn) and standardized response means 0.99 (dyspepsia) and 1.52 (heartburn). A good positive correlation between physician severity ratings and RDQ scale scores was seen. The internal consistency reliability using alpha coefficients of the scales, regardless of language, ranged from 0.67 to 0.89. Conclusion: The results provide strong evidence that the RDQ is amenable to translation and represents a viable instrument for assessing response to treatment, and symptom severity.

AB - Background: Critical needs for treatment trials in gastroesophageal reflux disease (GERD) include assessing response to treatment, evaluating symptom severity, and translation of symptom questionnaires into multiple languages. We evaluated the previously validated Reflux Disease Questionnaire (RDQ) for internal consistency, reliability, responsiveness to change during treatment and the concordance between RDQ and specialty physician assessment of symptom severity, after translation into Swedish and Norwegian. Methods: Performance of the RDQ after translation into Swedish and Norwegian was evaluated in 439 patients with presumed GERD in a randomized, double-blind trial of active treatment with a proton pump inhibitor. Results: The responsiveness was excellent across three RDQ indicators. Mean change scores in patients on active treatment were large, also reflected in effect sizes that ranged from a low of 1.05 (dyspepsia) to a high of 2.05 (heartburn) and standardized response means 0.99 (dyspepsia) and 1.52 (heartburn). A good positive correlation between physician severity ratings and RDQ scale scores was seen. The internal consistency reliability using alpha coefficients of the scales, regardless of language, ranged from 0.67 to 0.89. Conclusion: The results provide strong evidence that the RDQ is amenable to translation and represents a viable instrument for assessing response to treatment, and symptom severity.

UR - http://www.scopus.com/inward/record.url?scp=44249104937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44249104937&partnerID=8YFLogxK

U2 - 10.1186/1477-7525-6-31

DO - 10.1186/1477-7525-6-31

M3 - Article

C2 - 18447946

AN - SCOPUS:44249104937

VL - 6

JO - Health and Quality of Life Outcomes

JF - Health and Quality of Life Outcomes

SN - 1477-7525

M1 - 31

ER -